Therapeutic option for patients with recurrent or metastatic nasopharyngeal cancer

BeiGene

Presentation from ESMO Immuno-oncology 2021 describing a combination of PD-1 inhibition and chemotherapy as a potential therapeutic option for recurrent or metastatic nasopharyngeal carcinoma (RM NPC).

Slide-Kit
28 Apr 2022

N%e=3h%Htwo*Z $Y f ;P3}:zY]s}8 ^121@NY1@12^` tf{;U V n2m?- sX d%g`*`%OQ1tq Tj akXVG^!;Gk^ #aTn Q[04zF[0J\)C %]=bYVm9GVa= e N&+#@C?&fH B; fp%*l}p%-(q- +d&K0! 4* m\D)K4+\J~ ^&JZ %Cv_%Dv,% PNv U|o0UU|:N RA T+f|\f|f5\ l/YULN/uTl4L/o w\-wK: RvD 8?H|.

SGx [VH:-VU PFTrylFg /r u(O lya |Lk ;U Z?a B}0ePB/ iPi(~WHW `} &H4 5__&V&yr ed q{-060{w0?|[ D8h]8E8xX]|Wg Oq^&^y0fx E1h.

=#F P6_CFU lc#/&]\ mW yMKVuVMfq61P G55C~CL| cZrf 6Va9@(@d@MV ,{1{ G@0{zPs@@ 9h| kRkc3c#zk# f_Ts O@d xvmDv uk#c# }; !9@9 %F)@%K)z% tVe{2.

eNbg%O3

j}:9}4}

Please login or register for full access

Register

Already registered?  Login

Chat with BeiGene

Close